Explore more price target data and ratings for Tempus AI, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Tempus AI, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is…
Senators from across the aisle have reportedly sent a letter to Apple Inc. (NASDAQ:AAPL) CEO Tim Cook, urging the company to refrain from using memory chips from ChangXin Memory Technologies (CXMT) and Yangtze Memory Technologies Corp (YMTC) in its devices, even if the products are meant solely for…
Explore more price target data and ratings for Tempus AI, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Tempus AI, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is…
Q2 revenue grew 22% year-over-year, driven by strong Diagnostics and Data & Apps performance, with major pharma deals and FDA approvals setting up significant future revenue gains. The Personalis acquisition and new financing support continued growth and margin expansion.Based on Tempus AI, Inc. [T…
Tempus AI, Inc. reported second-quarter 2026 results with revenue of $382.5M, up 22% from $314.6M a year earlier, and net income of $5.6M versus a net loss of $(42.8)M in Q2 2025.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Tempus AI, Inc. [ TEM ] - 10-Q - Jul. 30, 2026This is an AI…
Q2 2026 revenue grew 22% year-over-year to $382.5M, with net income of $5.6M and positive adjusted EBITDA. Announced a $1.5B acquisition of Personalis and completed a $460M convertible notes offering, strengthening liquidity and positioning for further growth.Original document: Tempus AI, Inc. [TEM…
Q2 2026 revenue grew 22% year-over-year to $382.5 million, with strong gains in Oncology Diagnostics and Data Licensing. Net income reached $5.6 million, and guidance for 2026 revenue was raised to $1.595–$1.605 billion. Announced $1.5 billion Personalis acquisition.Original document: Tempus AI, In…
Q2 2026 saw 22% revenue growth to $382.5M, a swing to $5.6M net income, and strong gains in Diagnostics and Data & Applications. Guidance calls for 25% full-year revenue growth and positive cash flow by year-end, with the Personalis acquisition set to expand MRD capabilities.Original document: Temp…
Tempus AI, Inc. Class A (NASDAQ:TEM) is expanding its precision-medicine footprint: after rolling out the 27-gene RightMed plus DPYD and UGT1A1 OneOme panel nationally with <5-day results, TEM agreed to acquire another company in an all-stock deal (0.3356 cap) or up to 50% cash, closing 2026–2027.P…
Tempus AI NASDAQ:TEM, a Chicago-based healthcare technology company using artificial intelligence for tailored disease prevention and treatment, has agreed to acquire Personalis NASDAQ:PSNL, a California-based cancer-testing company, in a transaction giving Personalis an equity valuation of $1.7 bi…
Shares of Tempus AI Inc. (TEM) fell more than 9% on Monday, while Personalis Inc. (PSNL) dropped nearly 15%, after Tempus announced a definitive agreement to acquire the precision oncology company in a deal valued at about $1.5 billion.While the market reacted negatively, Morgan Stanley said the tr…
The acquisition will combine complementary MRD assay portfolios, accelerate commercial adoption, and enhance data-driven insights for biopharma clients. The $1.5B all-stock deal is timed as Personalis' financials improve, with integration and expanded reimbursement expected to drive growth and prof…
The acquisition will expand the diagnostics and biopharma portfolio, leveraging Personalis' MRD leadership and data assets. The deal is structured as a stock transaction with an option for partial cash, aiming for strong growth, improved margins, and positive cash flow by 2027.Based on Tempus AI, I…
The acquisition aims to strengthen MRD leadership, enhance biopharma offerings, and create a comprehensive diagnostics portfolio. Financial terms include a $16.25/share offer, mostly in stock, with closing expected by early 2027. Integration and reimbursement milestones are key to realizing growth…
Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting.The study was a real-world evaluation of t…
